Skip to main content
2025 AAPD Annual Meeting Main banner
Cheng Crowns
Information & Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticket Required
Ticket Required
Sold Out
Sold Out
Recorded Session
Recorded Session
Rate ePoster

Pulp Therapy

80 - Clinical and Radiographic Survival of Oxymetazoline Pulpotomies on Primary Molars

Friday, May 23, 2025
12:20 PM - 12:40 PM MDT
Has Audio

    Presenting Author(s)

  • CL

    Christine H. Lee, DMD

    Pediatric Dental Resident
    University of Minnesota, Minneapolis, MN
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Research Mentor(s)

  • Robert S. Jones, DDS, PhD

    Research Mentor
    University of Minnesota
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Program Director(s)

  • Jeff Karp, D.M.D., M.S.

    Residency Program Director
    University of Minnesota
    School of Dentistry , University of Minnesota
    Minneapolis, Minnesota, United States

Abstract:



Purpose: The aim of this retrospective study was to assess the clinical and radiographic survival of primary pulpotomies performed with different hemostatic agents and pulp capping materials.




Methods: After IRB approval, patient charts, from 2018 to 2023 at the University of Minnesota pediatric dental clinic, of children receiving primary molar pulpotomies were analyzed.  Patient and provider level factors were assessed including the use of secondary hemostatic agents (ferric sulfate (FS), nasal spray containing oxymetazoline (NS-OXY)) and pulp capping materials (IRM, MTA).  Clinical survival was assessed through progress notes/treatment plans.  




Results: Results are still pending.  For radiographic analysis, a single blinded experienced pediatric dentist assessed radiographs. Kaplan-Meier survival curve will be used to plot clinical and radiographic survival of NS-OXY/MTA, NS-OXY/IRM and FS/IRM pulpotomies.  Various patient and provider specific factors will be analyzed in a Cox hazard model. 




Conclusions: With an active alpha-agonist ingredient that creates hemostasis through temporary vasoconstriction, NS-OXY is used to create secondary pulpal hemostasis and this study will be one of the first to assess its effect on pulpotomy survival rates.

Identify Supporting Agency and Grant Number: